AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00647491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 20 mg sc eow
Study NCT00647491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg sc eow
Study NCT00647491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 80 mg sc eow
Study NCT00647491 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo sc eow
Study NCT02108990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study NCT04971278 — intervention group
Intervention type: BEHAVIORAL
Intervention: Supportive care program
Description: Community Health Workers, a home visiting doctor service, a supportive care nurse, and behavioral health specialist engage the population to address a range of biopsychosocial needs with end goal in increasing support in the community and engaging palliative and hospice care when appropriate to prevent hospital readmissions, shorten length of stay, reduce hospital utilization, and decrease overall patient cost with a focus on hospital spend.
Study NCT00493298 — intervention group
Intervention type: DRUG
Intervention: Tysabri
Description: According to the local prescribing information
Study NCT03741452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transversalis fascia plane block
Description: patient controlled analgesia devices with tramadol
Study NCT04417322 — intervention group
Intervention type: OTHER
Intervention: observation of serum A.actinomycetemcomitans levels
Description: Analysis of serum A.actinomycetemcomitans levels
Study NCT03650309 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: All patients will undergo surgical implantation of a deep brain stimulation (DBS) system, which involves placement of stimulating electrodes in the brain. These electrodes will be used to deliver electrical current to target two brain structures involved in the pathophysiology of obesity.
Study NCT01096277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: oral tablets 100 mg per day for two weeks
Study NCT01096277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet, one per day for two weeks
Study NCT01096277 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: no intervention
Study NCT02810574 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Study NCT02810574 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive training
Study NCT02810574 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive brain stimulation (active)
Description: Neuroconn DC-STIMULATOR PLUS
Study NCT02810574 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Noninvasive brain stimulation (sham)
Description: Neuroconn DC-STIMULATOR PLUS
Study NCT01014533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dispensed to subject.
Description: Placebo for 11 days, (one pill at bedtime on nights 1 and 2, 2 pills at bedtime on nights 3-10, and 1 pill at bedtime on night 11, then D/C). They return to the Sleep Lab for polysomnography on nights 8 - 10 of medication so their sleep data can be compared.
Study NCT01014533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin dispensed to subject.
Description: After spending 3 baseline nights in the UM Sleep Lab, alcohol dependent subjects are randomized to receive either gabapentin or placebo for 11 days. (1 pill (600 mg) at bedtime on nights 1 and 2, 2 pills (totalling 1200 mg) at bedtime on nights 3-10, and 1 pill (600 mg) at bedtime on night 11, then D/C). On nights 8 - 10 of medication, subjects return to the lab and sleep 3 more nights with the same procedures.
Study NCT03053154 — intervention group
Intervention type: OTHER
Intervention: Sagittal pelvic tilt assessment
Description: Each group passed by three phases of assessment. Firstly assess the pelvic tilt angles from sitting position. Secondly assess the pelvic tilt angles from dynamic sit to stand task. Thirdly, assess the ability to perform sit to stand task of each participant.
Study NCT01326754 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Artemether-lumefantrine combination
Description: Dispersible formulation of artemether-lumefantrine at a dose of 2/12 mg/kg body weight of artemether and lumefantrine, respectively, per dose, given twice a day for 3 days
Study NCT01326754 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Artesunate-amodiaquine combination
Description: Co-formulated artesunate-amodiaquine at a dose of 4 mg/kg/day artesunate and 10 mg/kg/day amodiaquine once a day for 3 days
Study NCT01326754 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dihydroartemisinin-piperaquine
Description: Co-formulated dihydroartemisinin-piperaquine at a dose of 4 mg/kg/day dihydroartemisinin and 18 mg/kg/day piperaquine once a day for 3 days
Study NCT03856554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral Transforaminal Interbody fusion
Description: TLIF via unilateral factectomy and insertion of one cage
Study NCT03856554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Transforaminal Interbody fusion
Description: TLIF via bilateral factectomy and insertion of two cages
Study NCT01535560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-60371, 0.3% otic suspension
Description: Investigational otic suspension intended for the treatment of acute otitis externa
Study NCT01535560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-60371 Vehicle
Description: Inactive ingredients used as placebo
Study NCT03019731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-directed Behavioral Therapy
Description: The therapist-directed behavioral therapy group will have their first appointment scheduled within one week of assignment. In the Therapist-directed face-face training program, training instructions will be manualized, in order to match the parent instructional guidelines provided in the home-based DVD. This manual will include the specific psychoeducation, awareness training, competing response training, differential reinforcement of incompatible behaviors, and other adaptive behavioral instructions contained within the home-based DVD. The therapist will match the sequence and required components within the behavior-based training DVD. Face-face training will be administered across 10 weeks (6 weekly sessions followed by 2 bi-weekly sessions).
Study NCT03019731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based DVD Therapy
Description: In order to mimic the slight delay between randomization and start of the therapist-directed treatment, those assigned to the Home-based DVD cohort will have the DVD and training materials mailed to their homes. Parents will also receive a written instructional form and a log sheet for tracking the use of the DVD and the time and duration of practice sessions. Any questions regarding patient care and treatment will be directed to Dr. Singer.
Study NCT02009761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: subcutaneous injection
Study NCT02596165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse wave analysis measurement with Schiller BR-102 Plus PWA device
Description: Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device
Study NCT04379726 — intervention group
Intervention type: BEHAVIORAL
Intervention: therapeutic optimization
Description: patients with diagnosis of CFRD will undergo the gold standard treatment for the disease (insulin therapy)
Study NCT01598623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 24 IU Intranasal, three times daily (morning, noon and evening, before meals) for 3 weeks (21 days).
Study NCT01598623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: three times a week for three weeks.
Study NCT01598623 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Non Specific Counselling
Study NCT01815138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger
Study NCT01815138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger
Study NCT03770533 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MR-proADM guided
Description: MR-proADM value together with routine clinical evaluation identifies patients with a low 14 day mortality risk who do not need to be hospitalized
Study NCT02647216 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Cognitive Therapy
Description: Weekly MBCT sessions consist of: a) mindfulness practice including breath-focused sitting meditation, body scanning, and mindful stretching; b) review of previous weeks' homework and an overview of the current week's homework; c) barriers to completing the homework. Homework includes: a) practicing the mindfulness exercise reviewed in class using the CDs provided to each participant (guided practice of the relevant exercise); b) maintaining a calendar of pleasant events; c) mindfully engaging in activities of daily living; and d) logging practice efforts in a daily log.
Study NCT02538510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02647216 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Subjects randomized to the Treatment as Usual group will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study.
Study NCT02538510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02538510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO or via PEG
Study NCT06596720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: After the initial assessments of the individuals in the study group were completed, the exercise program was implemented. The exercise program consisted of 30 minutes of submaximal cycling using the Karvonen formula. The aerobic exercise program was structured with a 5-minute warm-up, a 5-minute cool-down, and the remaining time dedicated to the exercise phase. Since our study included only a single exercise session, a moderate-intensity training program was applied to the participants.
Study NCT02328339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tea
Description: Black tea infusion equivalent to approximately 530 mg total polyphenols expressed as gallic acid equivalents
Study NCT02328339 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to tea with respect to taste and appearance
Study NCT02335528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SimCoach
Study NCT04307420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sonic Fill Restoration
Description: Kerr's Sonic Fill is the only sonic-activated, single-step, bulk-fill composite that starts out as a low-viscosity composite.
Study NCT04307420 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Composite Resin Restoration
Description: Composite resins are polymer-based materials used in dentistry for aesthetic repairs.Polymerization is accomplished typically with a hand held curing light that emits specific wavelengths keyed to the initiator and catalyst packages involved.
Study NCT02708914 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: UB-851
Description: UB-851 (rhEPO) has been developed as a biosimilar product to Eprex®.
Study NCT02708914 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Eprex
Description: Eprex® is chosen as the comparator.
Study NCT00622258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolmus
Study NCT00804089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional needle acupuncture
Description: Traditional needle acupuncture using traditional meridian acupoints and Ashi (tender) points
Study NCT00804089 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial trigger point dry needling
Description: Superficial dry needling of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
Study NCT00804089 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial trigger point acupressure
Description: Blunt needle acupressure of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
Study NCT04137094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persuasive Health Communication Intervention
Description: A persuasive health communication intervention will be performed
Study NCT00650351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin Extended-Release Tablets 1000 mg
Description: 1000mg, single dose fed
Study NCT00650351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cipro® XR Tablets 1000 mg
Description: 1000mg, single dose fed
Study NCT04552483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide 500mg 8/8 hours for 5 days in the early clinical phase of COVID-19.
Study NCT04552483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 8/8 hours for 5 days in the early clinical phase of COVID-19.
Study NCT02876276 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid filler
Description: Papillary augmentation with HA dermal fillers was considered as the test group
Study NCT02876276 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic acid filler
Description: Papillary augmentation with HA dermal fillers was considered as the test group
Study NCT00645047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine CBT
Description: Use of Videoconfrence Technology To Provide Cognitive Therapy
Study NCT00645047 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person CBT
Description: In-Person Provision Of Cognitive Therapy
Study NCT03219515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gongjin-Dan
Description: Gongjin-dan (Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea) is composed of Cervi Parvum, Angelica Gigas Root, Cornus Fruit, Ginseng, Steamed Rehmannia Root, and Musk.
Study NCT03219515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drugs (similar in appearance, taste, and odor to the Gongjin-dan) contains excipients, coloring agents, binders, flavoring agents, and preservative, and gilt-paper covering. Placebo pills of Gongjin-dan will be also made by Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea.
Study NCT03002753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: detached mindfulness
Description: Please see detailed study description.
Study NCT03002753 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive restructuring
Description: Please see detailed study description.
Study NCT01091077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Naringenin
Description: 1 gram of naringenin mixed with 16 grams of hydroxypropyl-β-cyclodextrin in 250 mL of water
Study NCT01981395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenobam
Description: Fenobam 150 mg will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
Study NCT01981395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
Study NCT03402490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Study NCT00557180 — intervention group
Intervention type: DRUG
Intervention: Beclomethasone dipropionate HFA
Description: Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
Study NCT00557180 — intervention group
Intervention type: DRUG
Intervention: Tiotropium bromide
Description: Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
Study NCT06601855 — intervention group
Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Cholecystectomy, whether open or laparoscopic
Study NCT00557180 — intervention group
Intervention type: DRUG
Intervention: Salmeterol xinafoate
Description: Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
Study NCT04054518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (MEDI4736) will be supplied as a 500-mg vial solution for infusion after dilution.
Study NCT04467528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Experimental: Electroacupuncture combined with conventional drug therapy~Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial~For participants with abdominal distension:~Electroacupuncture will be applied to the acupoints (LI4, PC6, ST36, SP6) 30min~For participants with post-operative ileus:~Electroacupuncture will be applied to the acupoints (LI4, SJ6, ST36, ST37) 30min~32# acupuncture needle used and twice daily for three days
Study NCT04467528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional drug therapy
Description: Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial
Study NCT04467528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional drug therapy
Description: Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial
Study NCT04435210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Description: Participants in this group will receive 10mg of hydralazine intravenously. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses.
Study NCT04435210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: Participants in this arm will receive 20mg of nifedipine and the blood pressure will be measured 30 minutes after the dose. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses
Study NCT01322997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myomo e100 Robot and repetitive task specific training
Description: Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include about 1/2 an hour of use of a robot that targets arm function and assists with the movement of the affected arm, and about 1/2 an hour of repetitive task specific training (TRP) using the affected arm.
Study NCT01322997 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive task specific training (RTP) targeting the affected arm
Description: Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include consist of repetitive task specific training (RTP) using the affected arm, in which patients use the arm to relearn valued movements using their arms.
Study NCT01322997 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Myomo e100 neurorobotic brace
Description: Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. Subjects will use a robot that targets arm function and assists with the movement of the affected arm.
Study NCT01810601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRh, HMG, HCG, Progesterone
Description: GnRh analogue (0.05 mg/day), HMG (150-300 iu/day), HCG (5000 iu/day), Progesterone (100 mg/day)
Study NCT01810601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GnRh, HMG, HCG, Progesterone
Description: GnRh analogue (0.05 mg/day), HMG (150-300 iu/day), HCG (5000 iu/day), Progesterone (100 mg/day)
Study NCT03753737 — intervention group
Intervention type: OTHER
Intervention: Questionnaires and semi-structured interview
Description: * Questionnaires : PDQ-4+ (personality disorders), HAD (Anxiety and Depression), AUDIT-c (Alcohol consumption), CTQ-SF (Childhood Trauma Questionnaire).~* Semi-structured interview : Evaluation of socio-demographic characteristics, psychiatric and addiction comorbidities, sexually transmitted infections, sexual practices, sexual dysfunction, hypersexual disorder.